At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 24 enrolled
Drug / intervention
Ziprasidonedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Trial of Ziprasidone as an Adjuvant for Clozapine- or Olanzapine-Associated Diabetes Mellitus or Impaired Fasting Glucose in Chronic Schizophrenia
In Brief
A Phase 4 clinical trial evaluating Ziprasidone for Schizophrenia. Completed, enrolled 24 participants across 1 site.
Detailed Summary
This study is a six-week, open label trial of the novel antipsychotic agent, ziprasidone, added to a stable dose of clozapine or olanzapine in 40 diabetes mellitus patients, patients with an impaired fasting glucose or insulin resistance with schizophrenia or schizoaffective disorder. The first two weeks will be a fixed-dose of ziprasidone 40 mg twice a day. During weeks 2-6, the ziprasidone dose may be increased up to 80 mg twice a day.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
CollaboratorsPfizer
Timeline
Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2005
First PostedJul 2006
Study CompletionMar 2007
TodayJul 2026
First PostedJul 12, 2006
Enrollment StartJan 1, 2005
Study CompletionMar 1, 2007
TodayJul 2, 2026
Posted 20.0 years ago
Interventions
Ziprasidonedrug